Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 600 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo + insulin Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation

NCT01354964
View directory record Official record
Conditions
Insulin Resistance
Interventions
Vitamin D, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 30, 2026, 9:51 AM EDT
Withdrawn Phase 2 Interventional

A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin

NCT01275027
View directory record Official record
Conditions
Diabetes
Interventions
Nutralin
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 30, 2026, 9:51 AM EDT
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 4 Interventional

Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes

NCT00398853
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
chromium picolinate 1000 mcg daily vs placebo, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
25 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

NCT02124759
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Sevelamer, Synbiotic, Maltodextrin, High Fat diet, Low Fat diet
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

NCT03310359
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 30, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions

NCT05564273
View directory record Official record
Conditions
Metabolic Health
Interventions
VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
Combination Product · Dietary Supplement
Lead sponsor
Viome
Industry
Eligibility
25 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

NCT00768105
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Sep 30, 2026, 9:51 AM EDT
Not listed Phase 2 Interventional

Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women

NCT00005769
View directory record Official record
Conditions
Menopause
Interventions
Hormone Replacement Therapy
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
45 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 9:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Steroids in Obese Men

NCT00983554
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Anastrazole, Testosterone, Dutasteride, GnRH antagonist
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
24 Years to 51 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D Deficiency, Insulin Resistance and FGF-23

NCT00491322
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Ergocalciferol, Ergocalciferol placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 30, 2026, 9:51 AM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04754334
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Deficiency in Adolescent Girls

NCT01180946
View directory record Official record
Conditions
Healthy, Vitamin D Deficiency
Interventions
ergocalciferol, placebo pill
Dietary Supplement · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

NCT02140983
View directory record Official record
Conditions
Insulin Resistance, Dementia
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer

NCT02124681
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 30, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

NCT03052400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Mifepristone 600 mg daily, Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

NCT01141192
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
vitamin D3, cholecalciferol, Inactive comparator
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 30, 2026, 9:51 AM EDT
Withdrawn Phase 2 Interventional

Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI

NCT02585765
View directory record Official record
Conditions
Spinal Cord Injury, Pressure Ulcers
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IR and Microvascular Blood Flow in SCI

NCT02034331
View directory record Official record
Conditions
Spinal Cord Injury, Insulin Resistance
Interventions
Insulin iontophoresis, Placebo Iontophoresis, Acetylcholine Iontophoresis, Heat application
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

NCT00146289
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
MICARDIS® (telmisartan)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Westlake Village, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Sep 30, 2026, 9:51 AM EDT
Recruiting Phase 2 Interventional

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417
View directory record Official record
Conditions
Parkinson Disease
Interventions
INS-GSH, Matched Placebos
Drug
Lead sponsor
Gateway Institute for Brain Research
Industry
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 30, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 30, 2026, 9:51 AM EDT